MedTrace Logo

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

NCT03417687 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-06-28

Study results available
· View outcomes & findings →

Summary

This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung resection.

Conditions

  • Pulmonary Surgical Procedures

Interventions

DRUG

129Xe MRI

Evaluation of pulmonary function

DRUG

133 Xe scintigraphy

Evaluation of pulmonary function

Sponsors & Collaborators

  • Polarean, Inc.

    lead INDUSTRY

Principal Investigators

  • Kenneth P West · Polarean, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-17
Primary Completion
2019-10-31
Completion
2020-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417687 on ClinicalTrials.gov